Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice

Frontiers in Aging Neuroscience

Volumn 6, Issue SEP, 2014, Pages

  Castro Alvarez, John F ^a   Alejandro Uribe Arias, S ^a   Kosik, Kenneth S ^b   Cardona Gómez, Gloria P ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; CDK5RNAi; Cognitive dysfunction; Long term gene therapy; Tau pathology

Indexed keywords

CYCLIN DEPENDENT KINASE 5; SHORT HAIRPIN RNA;

3XTG MOUSE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE SILENCING; GENE THERAPY; HIPPOCAMPAL CA1 REGION; HISTONE PHOSPHORYLATION; LEARNING TEST; LONG TERM CARE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; RNA INTERFERENCE; RNA SEQUENCE; SHORT COURSE THERAPY; SIMIAN VIRUS 40; SPATIAL LEARNING; SPATIAL MEMORY; TAUOPATHY;

EID: 84907927372     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00243     Document Type: Article

References (51)

1. Alvarez, A., Toro, R., Caceres, A., and Maccioni, R. B. (1999). Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett. 459, 421-426. doi: 10.1016/S0014-5793(99)01279-X
2. Augustinack, J. C., Schneider, A., Mandelkow, E. M., and Hyman, B. T. (2002). Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103, 26-35. doi: 10.1007/s004010100423
3. Bankiewicz, K. S., Forsayeth, J., Eberling, J. L., Sanchez-Pernaute, R., Pivirotto, P., Bringas, J.,et al. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther. 14, 564-570. doi: 10.1016/j.ymthe.2006.05.005
4. Billings, L. M., Oddo, S., Green, K. N., Mcgaugh, J. L., and Laferla, F. M. (2005). Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688. doi: 10.1016/j.neuron.2005.01.040
5. Boudreau, R. L., Mcbride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J.,et al. (2009). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 17, 1053-1063. doi: 10.1038/mt.2009.17
6. Boudreau, R. L., Monteys, A. M., and Davidson, B. L. (2008). Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14, 1834-1844. doi: 10.1261/rna.1062908
7. Boye, S. L., Conlon, T., Erger, K., Ryals, R., Neeley, A., Cossette, T.,et al. (2011). Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (GC1KO) mouse. Invest. Ophthalmol. Vis. Sci. 52, 7098-7108. doi: 10.1167/iovs.11-7867
8. Cardona-Gómez, P., Perez, M., Avila, J., Garcia-Segura, L. M., and Wandosell, F. (2004). Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol. Cell. Neurosci. 25, 363-373. doi: 10.1016/j.mcn.2003.10.008
9. Castro-Alvarez, J. F., Gutierrez-Vargas, J., Darnaudery, M., and Cardona-Gómez, G. P. (2011). ROCK inhibition prevents tau hyperphosphorylation and p25/CDK5 increase after global cerebral ischemia. Behav. Neurosci. 125, 465-472. doi: 10.1037/a0023167
10. Chang, K., Elledge, S. J., and Hannon, G. J. (2006). Lessons from Nature: microRNA-based shRNA libraries. Nat. Methods 3, 707-714. doi: 10.1038/nmeth923
11. Clinton, L. K., Billings, L. M., Green, K. N., Caccamo, A., Ngo, J., Oddo, S.,et al. (2007). Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol. Dis. 28, 76-82. doi: 10.1016/j.nbd.2007.06.013
12. Crews, L., Patrick, C., Adame, A., Rockenstein, E., and Masliah, E. (2011). Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death Disease 2, e120. doi: 10.1038/cddis.2011.2
13. 5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483. doi: 10.1016/S0896-6273(03)00627-5
14. DeTure, M., Ko, L. W., Easson, C., and Yen, S. H. (2002). Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau. Am. J. Pathol. 161, 1711-1722. doi: 10.1016/S0002-9440(10)64448-3
15. Dong, Z., Bai, Y., Wu, X., Li, H., Gong, B., Howland, J. G.,et al. (2013). Hippocampal long-term depression mediates spatial reversal learning in the Morris water maze. Neuropharmacology 64, 65-73. doi: 10.1016/j.neuropharm.2012.06.027
16. Fu, A. K., Ip, F. C., Fu, W. Y., Cheung, J., Wang, J. H., Yung, W. H.,et al. (2005). Aberrant motor axon projection, acetylcholine receptor clustering, and neurotransmission in cyclin-dependent kinase 5 null mice. Proc. Natl. Acad. Sci. U.S.A. 102, 15224-15229. doi: 10.1073/pnas.0507678102
17. Greenberg, S. G., and Davies, P. (1990). A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. U.S.A. 87, 5827-5831. doi: 10.1073/pnas.87.15.5827
18. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986). Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A. 83, 4913-4917. doi: 10.1073/pnas.83.13.4913
19. Gulinello, M., Gertner, M., Mendoza, G., Schoenfeld, B. P., Oddo, S., Laferla, F.,et al. (2009). Validation of a 2-day water maze protocol in mice. Behav. Brain Res. 196, 220-227. doi: 10.1016/j.bbr.2008.09.002
20. Hawasli, A. H., Benavides, D. R., Nguyen, C., Kansy, J. W., Hayashi, K., Chambon, P.,et al. (2007). Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat. Neurosci. 10, 880-886. doi: 10.1038/nn1914
21. 5). New York: Springer. doi: 10.1007/978-0-387-78887-6
22. Kimura, T., Fukuda, T., Sahara, N., Yamashita, S., Murayama, M., Mizoroki, T.,et al. (2010). Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J. Biol. Chem. 285, 38692-38699. doi: 10.1074/jbc. M110.136630
23. Kosik, K. S., Joachim, C. L., and Selkoe, D. J. (1986). Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 83, 4044-4048. doi: 10.1073/pnas.83.11.4044
24. Kurt, M. A., Davies, D. C., Kidd, M., Duff, K., and Howlett, D. R. (2003). Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 14, 89-97. doi: 10.1016/S0969-9961(03)00084-6
25. Lee, M. S., Kwon, Y. T., Li, M., Peng, J., Friedlander, R. M., and Tsai, L. H. (2000). Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364. doi: 10.1038/35012636
26. Lee, V. M., Brunden, K. R., Hutton, M., and Trojanowski, J. Q. (2011). Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect. Med. 1, a006437. doi: 10.1101/cshperspect.a006437
27. Liang, B., Duan, B. Y., Zhou, X. P., Gong, J. X., and Luo, Z. G. (2010). Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J. Biol. Chem. 285, 27737-27744. doi: 10.1074/jbc. M110.117960
28. Mandelkow, E. M., and Mandelkow, E. (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect. Med. 2, a006247. doi: 10.1101/cshperspect.a006247
29. Medeiros, R., Kitazawa, M., Chabrier, M. A., Cheng, D., Baglietto-Vargas, D., Kling, A.,et al. (2012). Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am. J. Pathol. 181, 616-625. doi: 10.1016/j.ajpath.2012.04.020
30. Murphy, D. B., and Borisy, G. G. (1975). Association of high-molecular-weight proteins with microtubules and their role in microtubule assembly in vitro. Proc. Natl. Acad. Sci. U.S.A. 72, 2696-2700. doi: 10.1073/pnas.72.7.2696
31. 5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565. doi: 10.1016/S0896-6273(03)00259-9
32. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R.,et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421. doi: 10.1016/S0896-6273(03)00434-3
33. Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C.,et al. (2014). Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383, 1138-1146. doi: 10.1016/S0140-6736(13)61939-X
34. 5 activity and promotes neurodegeneration. Nature 402, 615-622. doi: 10.1038/45159
35. Paudel, H. K., Lew, J., Ali, Z., and Wang, J. H. (1993). Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268, 23512-23518.
36. Piedrahita, D., Hernandez, I., Lopez-Tobon, A., Fedorov, D., Obara, B., Manjunath, B. S.,et al. (2010). Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice. J. Neurosci. 30, 13966-13976. doi: 10.1523/JNEUROSCI.3637-10.2010
37. 5 regulation of NR2B. Neuron 81, 1070-1083. doi: 10.1016/j.neuron.2014.01.022
38. Querfurth, H. W., and LaFerla, F. M. (2010). Alzheimer's disease. N. Engl. J. Med. 362, 329-344. doi: 10.1056/NEJMra0909142
39. Reitz, C., Brayne, C., and Mayeux, R. (2011). Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7, 137-152. doi: 10.1038/nrneurol.2011.2
40. Tsai, L. H., Delalle, I., Caviness, V. S. Jr., Chae, T., and Harlow, E. (1994). p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423. doi: 10.1038/371419a0
41. Urabe, M., Ding, C., and Kotin, R. M. (2002). Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13, 1935-1943. doi: 10.1089/10430340260355347
42. 5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors. Nat. Neurosci. 6, 1039-1047. doi: 10.1038/nn1119
43. Wang, J. Z., Grundke-Iqbal, I., and Iqbal, K. (2007). Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur. J. Neurosci. 25, 59-68. doi: 10.1111/j.1460-9568.2006.05226.x
44. Wang, Y., Martinez-Vicente, M., Kruger, U., Kaushik, S., Wong, E., Mandelkow, E. M.,et al. (2009). Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum. Mol. Genet. 18, 4153-4170. doi: 10.1093/hmg/ddp367
45. 5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim. Biophys. Acta 1772, 473-483. doi: 10.1016/j.bbadis.2006.10.011
46. Zhang, M., Li, J., Chakrabarty, P., Bu, B., and Vincent, I. (2004). Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am. J. Pathol. 165, 843-853. doi: 10.1016/S0002-9440(10)63347-0
47. Zhang, X., Hernandez, I., Rei, D., Mair, W., Laha, J. K., Cornwell, M. E.,et al. (2013). Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models. J. Biol. Chem. 288, 22042-22056. doi: 10.1074/jbc. M112.436402
48. Zheng, M., Leung, C. L., and Liem, R. K. (1998). Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J. Neurobiol. 35, 141-159. doi: 10.1002/(SICI)1097-4695(199805)35:2<141::AID-NEU2>3.0.CO;2-4
49. 5-p25 hyperactivity and tau hyperphosphorylation. J. Biol. Chem. 285, 34202-34212. doi: 10.1074/jbc. M110.134643
50. 5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J. 24, 209-220. doi: 10.1038/sj.emboj.7600441
51. 5 activity and phosphorylation of tau protein in transfected cells. Eur. J. Biochem. 269, 4427-4434. doi: 10.1046/j.1432-1033.2002.03133.x